VEEV vs HUBS: Veeva Systems vs HubSpot Stock Comparison: AI Score, Valuation, Performance and Upside
Veeva Systems is a vertical SaaS company with near-monopoly software lock-in in pharmaceutical commercial and regulatory operations, while HubSpot is a horizontal SMB CRM platform that uses a freemium model to attract small businesses. Veeva has higher switching costs and more durable competitive position; HubSpot has a much larger TAM but faces more competition.
VEEV vs HUBS is vertical life sciences SaaS with deep switching costs versus horizontal SMB CRM with freemium growth — Veeva wins if pharma Vault migration sustains high retention; HubSpot wins if multi-hub expansion compounds per-customer revenue across a large SMB installed base.
VEEV holds the edge across 4 of 5 key metrics in this comparison. VEEV has delivered stronger 1-year price return (+8.93% vs -46.37%), though HUBS has the better forward P/E setup (15.70x vs 27.41x for VEEV). On fundamentals, HUBS is growing revenue faster (19.80%), while VEEV maintains the higher operating margin (29.64%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for VEEV (+4.76%) than for HUBS (-7.67%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want a vertical SaaS company with near-monopoly switching costs in pharma
- prefer life sciences software whose compliance requirements create permanent workflow dependency
- value Veeva's high margins and consistent free cash flow from a captive customer base
- are comfortable with slower growth in exchange for exceptionally high retention rates
- prefer a large-TAM horizontal CRM with freemium customer acquisition at scale
- value multi-hub expansion as an efficient path to increase revenue per customer over time
- believe HubSpot's SMB focus is defensible against enterprise CRM competition in smaller business segments
- are comfortable with more competitive dynamics in exchange for a much larger addressable market
| Metric | VEEV | HUBS |
|---|---|---|
| AI scorei | 56.5 | 42.9 |
| AI ranki | #230 | #691 |
| Latest closei | $313.03 | $238.91 |
| 1M returni | +17.41% | -1.26% |
| 3M returni | +58.60% | +6.39% |
| 6M returni | +86.67% | +7.14% |
| 1Y returni | +8.93% | -46.37% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VEEV | HUBS |
|---|---|---|
| 1Y ago | $10.69K (+6.9%) started 2025-10-16 | $5.52K (-44.8%) started 2025-10-16 |
| 5Y ago | $10.08K (+0.8%) started 2021-10-18 | $2.98K (-70.2%) started 2021-10-18 |
| 10Y ago | $82.44K (+724.4%) started 2016-10-17 | $46.39K (+363.9%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | VEEV | HUBS |
|---|---|---|
| Market capi | $45.45B | $13.34B |
| Trailing P/Ei | 46.10 | 92.44 |
| Forward P/Ei | 27.41 | 15.70 |
| Price/Salesi | N/A | 11.26 |
| EV/Revenuei | 11.02 | 3.45 |
| Analyst targeti | $294.07 | $240.69 |
| Target upsidei | +4.76% | -7.67% |
| Metric | VEEV | HUBS |
|---|---|---|
| Revenue growthi | 17.60% | 19.80% |
| Earnings growthi | 39.50% | 968.10% |
| EPS growthi | +39.50% | +968.10% |
| FCF margini | +36.37% | +19.33% |
| Operating margini | 29.64% | 4.87% |
| Profit margini | 29.34% | 4.26% |
| ROIC proxyi | 14.42% | 7.89% |
| Return on equityi | 14.42% | 7.89% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.92 | 1.17 |
| Debt/equityi | 2.04 | 14.30 |
| Current ratioi | 5.46 | 1.38 |
| Quick ratioi | 5.36 | 1.11 |
Over the past year, VEEV and HUBS have moved moderately in the same direction (correlation of 0.60), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VEEV | HUBS |
|---|---|---|---|
| 1Y | Growthi | +6.93% | -44.79% |
| CAGRi | +6.95% | -44.84% | |
| Volatilityi | 43.09% | 73.71% | |
| Sharpe ratioi | 0.26 | -0.50 | |
| Sortino ratioi | 0.41 | -0.67 | |
| Max drawdowni | 49.37% | 65.57% | |
| Current drawdowni | 0.00% | 51.69% | |
| Avg drawdowni | 27.64% | 44.59% | |
| Ulcer Indexi | 31.69% | 47.74% | |
| Max daily dropi | 9.77% | 19.10% | |
| Max wkly dropi | 16.81% | 27.02% | |
| 5Y | Growthi | +0.82% | -70.25% |
| CAGRi | +0.16% | -21.55% | |
| Volatilityi | 39.56% | 57.51% | |
| Sharpe ratioi | 0.09 | -0.21 | |
| Sortino ratioi | 0.13 | -0.30 | |
| Max drawdowni | 53.54% | 80.02% | |
| Current drawdowni | 3.76% | 71.96% | |
| Avg drawdowni | 34.46% | 45.77% | |
| Ulcer Indexi | 36.57% | 49.50% | |
| Max daily dropi | 16.24% | 19.10% | |
| Max wkly dropi | 21.64% | 27.02% | |
| 10Y | Growthi | +724.41% | +363.90% |
| CAGRi | +23.50% | +16.59% | |
| Volatilityi | 38.89% | 52.25% | |
| Sharpe ratioi | 0.62 | 0.47 | |
| Sortino ratioi | 0.93 | 0.68 | |
| Max drawdowni | 55.69% | 80.02% | |
| Current drawdowni | 8.20% | 71.96% | |
| Avg drawdowni | 22.72% | 27.18% | |
| Ulcer Indexi | 28.69% | 36.01% | |
| Max daily dropi | 16.24% | 19.10% | |
| Max wkly dropi | 21.64% | 28.86% |
| Category | VEEV | HUBS |
|---|---|---|
| Company | Veeva Systems Inc. | HubSpot, Inc. |
| Sector | Healthcare | Technology |
| Industry | Health Information Services | Software - Application |
| Core business | Vertical cloud software for the life sciences industry, providing CRM, regulatory content management, clinical data, and quality management applications. Veeva's Vault platform is the standard of care for pharmaceutical commercial and clinical operations. | CRM platform for marketing, sales, service, and operations primarily serving small and mid-size businesses. HubSpot's inbound marketing philosophy and freemium model attract SMBs that grow into paying multi-hub customers. |
| Investor focus | Vault platform migration and adoption, Clinical Data Cloud advancement, data and analytics revenue, and transition to industry cloud model. | Customer count growth, multi-hub adoption (Marketing Hub + Sales Hub + Service Hub), average contract value expansion, and operating margin improvement. |
- Vertical SaaS for pharma creates extremely deep switching costs — switching Veeva means replacing core commercial and regulatory workflows
- Life sciences industry regulation creates a constant demand for Veeva's compliance-centric applications
- Data cloud and analytics create upsell potential on top of core software with high incremental margins
- Freemium model creates a large top-of-funnel for customer acquisition that converts to paid plans as SMBs grow
- Multi-hub strategy increases revenue per customer as HubSpot adds Sales, Service, and Operations Hubs to Marketing Hub
- HubSpot's SMB market focus provides a massive addressable market that Salesforce and enterprise CRMs largely ignore
- Salesforce is developing a competing life sciences CRM that could threaten Veeva's commercial segment long-term
- Veeva's growth is tied to pharmaceutical industry R&D and commercial spending cycles
- Transition to Vault platform requires customer migrations that can be complex and time-consuming
- Microsoft Dynamics, Salesforce Essentials, and Monday CRM compete directly in the SMB CRM market
- Economic headwinds reduce SMB spending on software — HubSpot's growth is sensitive to SMB health
- AI-powered CRM from Salesforce and Microsoft could commoditize basic marketing automation features
Compare more than two at a time
This page is a fixed writeup on VEEV and HUBS. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside VEEV and HUBS, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.